NCT06273553View on ClinicalTrials.gov

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2027

Conditions
Human Papillomavirus Associated Intraepithelial NeoplasiaCervical Intraepithelial Neoplasia Grade 2/3Human Papillomavirus Type 16 InfectionHuman Papillomavirus Type 18 Infection
Interventions
BIOLOGICAL

RG002 injection

In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).

All Listed Sponsors
lead

RinuaGene Biotechnology Co., Ltd.

INDUSTRY

NCT06273553 - A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 | Biotech Hunter | Biotech Hunter